Elicio Therapeutics (ELTX) Convertible Debt (2024)
Elicio Therapeutics (ELTX) reported Convertible Debt of $20.0 million for Q4 2024, up 1.0% quarter-over-quarter from $19.8 million in Q3 2024.
Elicio Therapeutics (ELTX) Convertible Debt (2024) Analysis & Trends
Elicio Therapeutics has reported Convertible Debt for 1 years, with the latest figure at $20.0 million in Q4 2024.
- For the quarter ending Q4 2024, Convertible Debt changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Dec 2024 stood at $20.0 million (changed N/A YoY), and the FY2024 full-year result was $20.0 million, changed N/A from the prior year.
- Convertible Debt for Q4 2024 stood at $20.0 million, up from $19.8 million in the prior quarter.
- The five-year high for Convertible Debt was $20.0 million in Q4 2024, with the low at $19.8 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Elicio Therapeutics | 70.12 Mn | 55.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20.03 Mn |
| Sep 30, 2024 | 19.84 Mn |